Abstract
2 Acellular Small Diameter Long-bypass Grafts 1
Introduction 2
Synthetic artificial vascular grafts with inner diameters (IDs) larger than 6 mm are 3 frequently used for bypass grafts or replacements, and they provide good, long-term 4 clinical patency [1] . However, small-caliber vascular grafts with IDs smaller than 4 mm 5 cannot achieve patency due to acute thrombogenicity on the luminal surface and grafts have yet to be developed. One explanation for this may stem from the 18 discrepancies in required diameters and lengths between animal models and humans.
19
For a coronary artery or limb distal bypass graft to be clinically relevant, small-diameter 20 vascular grafts with IDs of less than 2 mm and lengths greater than 10 cm are required.
21
Indeed, the majority of previous efforts have focused on obtaining a much more 22 effective antithrombogenic surface, and the development of appropriate grafts yielding 23 good patency has not been achieved.
24
Rapid endothelialization on the luminal surface of the artificial graft must 25 inhibit the initial thrombosis and lead to long-term patency. In this study, we focused on 
33
To this end, decellularized ostrich carotid arteries were employed as the graft 34 material due to their straight and branchless structure. We have been studying larger 35 sized decellularized cardiovascular tissue using non-detergent technology [25, 26] and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   3 reported their good patency and performance. However we did not achieve high patency 1 in this thin and long vascular graft. The purpose of this study was to achieve the patency were assessed by transplanting to pig in the femoral-femoral artery crossover bypass 7 method. Gly-Gly-Gly-(Pro-Hyp-Gly) 7 peptide solution and incubated overnight at room 17 temperature. After the incubation, labeled peptide was purified with a PD-10 column.
18
Peptide modification was carried out using the same procedure. the same as those used in HUVEC cultures.
5
To evaluate the cell-binding efficiency for peptide-modified decellularized tissue, 6 porcine aortic tissue was selected. The tissue was decellularized using UHP treatment, incubated in a humidified atmosphere containing 95% air and 5% CO 2 at 37°C for 24 h.
13
The tissues were then washed three times with PBS, and adherent cells were eluted Grand Island, NY, USA) and DAPI solution (Dojin chemical Co., Kumamoto, Japan).
22
After staining, specimens were observed using the FV1000-D CLSM system (Olympus,
23
Tokyo, Japan).
25

Transplantation of grafts
26
All animal experiments were conducted in accordance with the Guidelines for 
Blood compatibility of grafts and neointima formation 12
To evaluate the very early stage thrombogenesis, the grafts were exposed to blood 
18
The peptide-modified graft was extirpated at 1 week to evaluate the 19 endothelialization. These experiments were separately carried out from the graft patency. The six transplanted peptide-modified grafts were exposed, and the patency was 
Results
34
The small diameter vascular grafts were prepared by the ultrahigh hydrostatic 35 pressure (UHP) decellularization and peptide modification of the ostrich carotid arteries 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 A decellularized ostrich carotid artery is shown in Figure 2a . The entire length 6 of the ostrich carotid artery was 80-90 cm, and the ID was 2 (distal) to 4 (proximal) mm.
7
Cell components were observed on native and UHP treatment tissues (Figure 2b ). On 8 the other hand, the components were not observed after UHP treatment and washing.
9
The remaining DNA in the tissue was not detected on the DNA quantification assay 
27
Peptide modification, shown in Figure 1 , was confirmed using a confocal laser OPG7G3REDV-modified decellularized tissues (Figure 3b) . Additionally, fibroblasts
35
(integrin α4β1-negative) were not able to efficiently adhere to either of these surfaces. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 clean, severe thrombogenesis was observed on the unmodified graft.
10
To evaluate the endothelium formation at an early period of time, the the peptide-modified graft at 7 days after transplantation was carried out. (Figure 6 ).
19
The von Wilbrand-positive and Vimentin-positive layer which was formed during 7 20 days was clearly observed. The cells were aligned on the luminal surface of the graft.
21
No von Kossa positive staining was observed in medium and outer layer of the graft.
22
The EVG staining result indicated the elastic fiber structure in the graft. 
Evaluation of patency in the transplanted grafts
25
The patency of the grafts was tested using a porcine femoral-femoral crossover 26 bypass (FF bypass) model. All unmodified grafts quickly occluded. Two unmodified 27 grafts were confirmed by taking out in one week and another one was in 27 days. In 33 Figure 7 shows the luminal surface of the unmodified and peptide-modified grafts.
34
The unmodified graft was covered by the severe coagulation and completely occluded
35
( Figure 7a ). In the case of peptide-modified graft, the luminal surface was clear, and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 We have developed here the small-caliber long bypass graft. As shown in the
10
Supplementary Movie 2, microscopic angioscopy observations at 20 days after 11 transplantation revealed a surprisingly white luminal surface and no thrombus formation.
12
These results clearly show that we succeeded in completely inhibiting thrombus and desirable for preparing the medical implants. Collagen mimetic peptide,
35
(Pro-Hyp-Gly) n has been reported to bind preferentially to collagen fibers in a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 strand-inversion manner [30] . We utilized this mechanism for surface modification of tissues. The initial thrombogenic formation was also suppressed by this modification.
8
Anticoagulation medicine is normally adopted during transplantation surgery for 9 controlling an activated clotting time. In our experiments, the heparin was used only 10 during the operation. Even in this situation, microthrombosis was induced on the naked 11 decellularized surface whereas thrombosis was not observed on the peptide-modified
12
surface. This may be due to the collagen being exposed to the blood stream, which is 
30
We hypothesize that it may be difficult for endothelial cells to be recruited to 31 the middle region at around 15 cm from the native intima at the suturing edge.
32
Moreover, we are currently investigating whether circulating endothelial progenitor 33 cells play a major role in the rapid neointima formation [32] . Minimal clotting at the 34 suturing point was observed. For future work, we plan to investigate the response and 35 patency of our grafts over longer periods. Immunogenicity of the graft in long-term 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 period is also important issue for evaluating of clinical application. Fundamentally, 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Takabayashi C, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 The transplanted tissues were stained with Hematoxylin and eosin (HE), von Kossa,
4
Elastica van Gieson (EVG), von Willebrand factor (vWF), and Vimentin (Vim) staining.
5
The scale bar is 50 μm. Asterisk indicates luminal side. 
